IRadimed Corporation (NASDAQ $IRMD) (+0%) is a company specializing in magnetic resonance imaging (MRI)-compatible medical devices, such as infusion pumps and non-magnetic vital monitors, designed to operate within the scanner without interfering with the magnetic field.
📊 Recent results
- Record revenues → The company sold more than ever: $20.4 million in the second quarter of 2025. That's 14% more than last year in the same period.
- Net profit → Earned $0.45 per share (on a clean basis), which is almost 20 % more than in 2024.
- Stable dividend → Paid its shareholders $0.17 per share, showing that it takes care of its investors.
- Outlook for 2025 → They expect to bill between $80 million and $82 million for the full year, with earnings between $1.60 and $1.70 per share.
🔑 Key points that make it attractive.
- Steady growth → 16 consecutive quarters of record earnings.
- Sustained dividends → $0.17 USD/share quarterly, with solid payout.
- Technological innovation → only company to offer infusion systems and operational non-magnetic monitors within MRI.
- Operational expansion → new plant in Florida (2025) to increase production capacity.
- Recognitions → ranked among the most successful small caps in the U.S. in 2024.
✅ Conclusion.
IRadimed is a clear example of a niche medical company with technological moat, strong growth and financial discipline. For the long-term investor looking for exposure to the healthcare sector, consistent cash generation and dividends, IRadimed is a stock to follow very closely.
